Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
Identifieur interne : 000574 ( PubMed/Curation ); précédent : 000573; suivant : 000575Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
Auteurs : Raymond A. Tetteh [Pays-Bas] ; Barbara A. Yankey [États-Unis] ; Edmund T. Nartey [Ghana] ; Margaret Lartey [Ghana] ; Hubert G M. Leufkens [Pays-Bas] ; Alexander N O. Dodoo [Ghana]Source :
- Drug safety [ 1179-1942 ] ; 2017.
Abstract
Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry " http://www.clinicaltrials.gov " and scholar.google, using combination search terms 'pre-exposure prophylaxis', 'safety concerns in the use of pre-exposure prophylaxis', 'truvada use as PrEP', 'guidelines for PrEP use', 'HIV pre-exposure prophylaxis' and 'tenofovir' to identify clinical trials and literature on PrEP. We present findings associated with safety issues on the use of PrEP based on a review of 11 clinical trials on PrEP with results on safety and efficacy as at April 2016. We also reviewed findings from routine real-life practice reports. The pharmacological intervention for PrEP was tenofovir disoproxil fumarate/emtricitabine in a combined form as Truvada(®) or tenofovir as a single entity. Both products are efficacious for PrEP and seem to have a good safety profile. Regular monitoring is recommended to prevent long-term toxic effects. The main adverse effects observed with PrEP are gastrointestinal related; basically mild to moderate nausea, vomiting and diarrhea. Other adverse drug effects worth monitoring are liver enzymes, renal function and bone mineral density. PrEP as an intervention to reduce HIV transmission appears to have a safe benefit-risk profile in clinical trials. It is recommended for widespread use but adherence monitoring and real-world safety surveillance are critical in the post-marketing phase to ensure that the benefits observed in clinical trials are maintained in real-world use.
DOI: 10.1007/s40264-017-0505-6
PubMed: 28130774
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000574
Links to Exploration step
pubmed:28130774Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.</title><author><name sortKey="Tetteh, Raymond A" sort="Tetteh, Raymond A" uniqKey="Tetteh R" first="Raymond A" last="Tetteh">Raymond A. Tetteh</name><affiliation wicri:level="1"><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. r_niiatetteh@yahoo.com.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Yankey, Barbara A" sort="Yankey, Barbara A" uniqKey="Yankey B" first="Barbara A" last="Yankey">Barbara A. Yankey</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Heath, Georgia State University, Atlanta, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Public Heath, Georgia State University, Atlanta, GA</wicri:regionArea></affiliation></author><author><name sortKey="Nartey, Edmund T" sort="Nartey, Edmund T" uniqKey="Nartey E" first="Edmund T" last="Nartey">Edmund T. Nartey</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea></affiliation></author><author><name sortKey="Leufkens, Hubert G M" sort="Leufkens, Hubert G M" uniqKey="Leufkens H" first="Hubert G M" last="Leufkens">Hubert G M. Leufkens</name><affiliation wicri:level="1"><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Dodoo, Alexander N O" sort="Dodoo, Alexander N O" uniqKey="Dodoo A" first="Alexander N O" last="Dodoo">Alexander N O. Dodoo</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28130774</idno><idno type="pmid">28130774</idno><idno type="doi">10.1007/s40264-017-0505-6</idno><idno type="wicri:Area/PubMed/Corpus">000574</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000574</idno><idno type="wicri:Area/PubMed/Curation">000574</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000574</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.</title><author><name sortKey="Tetteh, Raymond A" sort="Tetteh, Raymond A" uniqKey="Tetteh R" first="Raymond A" last="Tetteh">Raymond A. Tetteh</name><affiliation wicri:level="1"><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. r_niiatetteh@yahoo.com.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Yankey, Barbara A" sort="Yankey, Barbara A" uniqKey="Yankey B" first="Barbara A" last="Yankey">Barbara A. Yankey</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Heath, Georgia State University, Atlanta, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Public Heath, Georgia State University, Atlanta, GA</wicri:regionArea></affiliation></author><author><name sortKey="Nartey, Edmund T" sort="Nartey, Edmund T" uniqKey="Nartey E" first="Edmund T" last="Nartey">Edmund T. Nartey</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea></affiliation></author><author><name sortKey="Leufkens, Hubert G M" sort="Leufkens, Hubert G M" uniqKey="Leufkens H" first="Hubert G M" last="Leufkens">Hubert G M. Leufkens</name><affiliation wicri:level="1"><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Dodoo, Alexander N O" sort="Dodoo, Alexander N O" uniqKey="Dodoo A" first="Alexander N O" last="Dodoo">Alexander N O. Dodoo</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea></affiliation></author></analytic><series><title level="j">Drug safety</title><idno type="eISSN">1179-1942</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry " http://www.clinicaltrials.gov " and scholar.google, using combination search terms 'pre-exposure prophylaxis', 'safety concerns in the use of pre-exposure prophylaxis', 'truvada use as PrEP', 'guidelines for PrEP use', 'HIV pre-exposure prophylaxis' and 'tenofovir' to identify clinical trials and literature on PrEP. We present findings associated with safety issues on the use of PrEP based on a review of 11 clinical trials on PrEP with results on safety and efficacy as at April 2016. We also reviewed findings from routine real-life practice reports. The pharmacological intervention for PrEP was tenofovir disoproxil fumarate/emtricitabine in a combined form as Truvada(®) or tenofovir as a single entity. Both products are efficacious for PrEP and seem to have a good safety profile. Regular monitoring is recommended to prevent long-term toxic effects. The main adverse effects observed with PrEP are gastrointestinal related; basically mild to moderate nausea, vomiting and diarrhea. Other adverse drug effects worth monitoring are liver enzymes, renal function and bone mineral density. PrEP as an intervention to reduce HIV transmission appears to have a safe benefit-risk profile in clinical trials. It is recommended for widespread use but adherence monitoring and real-world safety surveillance are critical in the post-marketing phase to ensure that the benefits observed in clinical trials are maintained in real-world use.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28130774</PMID><DateCreated><Year>2017</Year><Month>01</Month><Day>28</Day></DateCreated><DateRevised><Year>2017</Year><Month>04</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.</ArticleTitle><Pagination><MedlinePgn>273-283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-017-0505-6</ELocationID><Abstract><AbstractText>Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry " http://www.clinicaltrials.gov " and scholar.google, using combination search terms 'pre-exposure prophylaxis', 'safety concerns in the use of pre-exposure prophylaxis', 'truvada use as PrEP', 'guidelines for PrEP use', 'HIV pre-exposure prophylaxis' and 'tenofovir' to identify clinical trials and literature on PrEP. We present findings associated with safety issues on the use of PrEP based on a review of 11 clinical trials on PrEP with results on safety and efficacy as at April 2016. We also reviewed findings from routine real-life practice reports. The pharmacological intervention for PrEP was tenofovir disoproxil fumarate/emtricitabine in a combined form as Truvada(®) or tenofovir as a single entity. Both products are efficacious for PrEP and seem to have a good safety profile. Regular monitoring is recommended to prevent long-term toxic effects. The main adverse effects observed with PrEP are gastrointestinal related; basically mild to moderate nausea, vomiting and diarrhea. Other adverse drug effects worth monitoring are liver enzymes, renal function and bone mineral density. PrEP as an intervention to reduce HIV transmission appears to have a safe benefit-risk profile in clinical trials. It is recommended for widespread use but adherence monitoring and real-world safety surveillance are critical in the post-marketing phase to ensure that the benefits observed in clinical trials are maintained in real-world use.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tetteh</LastName><ForeName>Raymond A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. r_niiatetteh@yahoo.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacy Department, Korle-Bu Teaching Hospital, Korle-Bu, Mamprobi, MP 2362, Accra, Ghana. r_niiatetteh@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yankey</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>School of Public Heath, Georgia State University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nartey</LastName><ForeName>Edmund T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Disease Control, School of Public Health, University of Ghana, Legon, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lartey</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leufkens</LastName><ForeName>Hubert G M</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicines Evaluation Board, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodoo</LastName><ForeName>Alexander N O</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):586-9</RefSource><PMID Version="1">22874836</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):65-8</RefSource><PMID Version="1">21270743</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2016 Jan 2;387(10013):53-60</RefSource><PMID Version="1">26364263</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Behav. 2013 Jul;17(6):2162-72</RefSource><PMID Version="1">23080358</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1997 Nov 20;337(21):1485-90</RefSource><PMID Version="1">9366579</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):447-56</RefSource><PMID Version="1">24135734</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):77-83</RefSource><PMID Version="1">19295337</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 2;367(5):423-34</RefSource><PMID Version="1">22784038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 2;367(5):399-410</RefSource><PMID Version="1">22784037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Feb 1;383(9915):399-400</RefSource><PMID Version="1">24494225</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 2;367(5):411-22</RefSource><PMID Version="1">22784040</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin HIV AIDS. 2016 Jan;11(1):10-7</RefSource><PMID Version="1">26633638</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2005 Feb 1;191 Suppl 1:S107-14</RefSource><PMID Version="1">15627220</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2014 Dec;61(6):1407-17</RefSource><PMID Version="1">25178562</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2006 Aug 16;296(7):863-5</RefSource><PMID Version="1">16905792</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):96-101</RefSource><PMID Version="1">16123689</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2014 Mar 04;11(3):e1001613</RefSource><PMID Version="1">24595035</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Dec 18;8(12):e81997</RefSource><PMID Version="1">24367497</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 2;367(5):459-61</RefSource><PMID Version="1">22784041</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2013 Jun 15;381(9883):2083-90</RefSource><PMID Version="1">23769234</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(7):e40603</RefSource><PMID Version="1">22792384</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2016 Jul 17;30(11):1731-43</RefSource><PMID Version="1">26752282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sex Transm Dis. 2008 Dec;35(12):1002-8</RefSource><PMID Version="1">19051397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Drug Saf. 2016;15(2):265-73</RefSource><PMID Version="1">26634852</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Public Health. 1999 Sep;89(9):1397-405</RefSource><PMID Version="1">10474559</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Feb 5;372(6):509-18</RefSource><PMID Version="1">25651245</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Dec 30;363(27):2587-99</RefSource><PMID Version="1">21091279</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Dec 3;373(23):2237-46</RefSource><PMID Version="1">26624850</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2006 Nov;3(11):e454</RefSource><PMID Version="1">17090213</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Patient Care STDS. 2012 Feb;26(2):87-94</RefSource><PMID Version="1">22149764</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):79-86</RefSource><PMID Version="1">23466649</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2010 Sep;55(1):8-13</RefSource><PMID Version="1">21423876</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Jul 28;380(9839):325</RefSource><PMID Version="1">22852138</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Clin Trials. 2007 May 25;2(5):e27</RefSource><PMID Version="1">17525796</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2012 Apr 24;26(7):F13-9</RefSource><PMID Version="1">22333749</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Sep 26;8(9):e74314</RefSource><PMID Version="1">24086333</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2011 Sep;23(9):1136-45</RefSource><PMID Version="1">21476147</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Saf. 2016 Nov;39(11):1139-1149</RefSource><PMID Version="1">27638659</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2011 Feb;66(2):240-50</RefSource><PMID Version="1">21118913</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2013;18(3):301-10</RefSource><PMID Version="1">22914267</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2009 Mar 15;48(6):806-15</RefSource><PMID Version="1">19193111</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2013 Nov;29(11):1443-50</RefSource><PMID Version="1">23600365</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28130774</ArticleId><ArticleId IdType="doi">10.1007/s40264-017-0505-6</ArticleId><ArticleId IdType="pii">10.1007/s40264-017-0505-6</ArticleId><ArticleId IdType="pmc">PMC5362649</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000574 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000574 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28130774
|texte= Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28130774" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |